Cargando…

Proteomic Analysis Reveals Low-Dose PARP Inhibitor-Induced Differential Protein Expression in BRCA1-Mutated High-Grade Serous Ovarian Cancer Cells

[Image: see text] High-grade serous ovarian cancer (HGSOC) is the most common form of ovarian cancer diagnosed in patients worldwide. Patients with BRCA1/2-mutated HGSOC have benefited from targeted treatments such as poly(ADP-ribose) polymerase inhibitors (PARPi). Despite the initial success of PAR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perez, Jesenia M., Twigg, Carly A. I., Guan, Weihua, Thomas, Stefani N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2021
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824432/ https://www.ncbi.nlm.nih.gov/pubmed/34958553 http://dx.doi.org/10.1021/jasms.1c00215

Ejemplares similares

Differential histone deacetylase inhibitor-induced perturbations of the global proteome landscape in the setting of high-grade serous ovarian cancer
por: Duda, Jolene M., et al.
Publicado: (2023)

PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer
por: Dickson, Kristie-Ann, et al.
Publicado: (2021)

Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer
por: Vendrell, Julie A., et al.
Publicado: (2023)

Invasive bilateral breast cancer and high grade serous ovarian cancer with BRCA1-germline mutation and brainstem metastasis under PARP inhibitors
por: Zahari, Mihaela Mărioara, et al.
Publicado: (2021)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer
por: Nicoletto, Maria Ornella, et al.
Publicado: (2023)

The Influence of PARP, ATR, CHK1 Inhibitors on Premature Mitotic Entry and Genomic Instability in High-Grade Serous BRCA(MUT) and BRCA(WT) Ovarian Cancer Cells
por: Gralewska, Patrycja, et al.
Publicado: (2022)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification
por: Gasimli, Khayal, et al.
Publicado: (2022)

Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer
por: Sahin, Irem Durmaz, et al.
Publicado: (2019)

BRCA1 mutations in high-grade serous ovarian cancer are associated with proteomic changes in DNA repair, splicing, transcription regulation and signaling
por: Bradbury, Melissa, et al.
Publicado: (2022)

Potent immunogenicity in BRCA1‐mutated patients with high‐grade serous ovarian carcinoma
por: Dai, Ying, et al.
Publicado: (2018)

NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer
por: Marchetti, Claudia, et al.
Publicado: (2021)

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
por: O’Sullivan, Ciara C., et al.
Publicado: (2014)

Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells
por: Jia, Yaxun, et al.
Publicado: (2022)

Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system
por: Bound, Nirashaa T., et al.
Publicado: (2022)

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer
por: van der Biessen, Diane A. J., et al.
Publicado: (2018)

PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival
por: Shao, Fengping, et al.
Publicado: (2021)

Exploring the Control of PARP1 Levels in High-Grade Serous Ovarian Cancer
por: Raspaglio, Giuseppina, et al.
Publicado: (2023)

The role of PARP inhibitors in BRCA mutated pancreatic cancer
por: Chi, Jeffrey, et al.
Publicado: (2021)

Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
por: Kanakkanthara, Arun, et al.
Publicado: (2022)

CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors
por: Lu, Xue, et al.
Publicado: (2022)

Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer
por: Kim, Se Ik, et al.
Publicado: (2019)

Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer
por: Boyarskikh, Ulyana A., et al.
Publicado: (2020)

Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer
por: Eoh, Kyung Jin, et al.
Publicado: (2020)

Germline and tumor BRCA1/2 mutations in Chinese high grade serous ovarian cancer patients
por: Ji, Gang, et al.
Publicado: (2021)

Natural phytochemicals prevent side effects in BRCA-mutated ovarian cancer and PARP inhibitor treatment
por: Wang, Chuanlin, et al.
Publicado: (2022)

Proteome profiling of low grade serous ovarian cancer
por: zadeh fakhar, Haniyeh Bashi, et al.
Publicado: (2019)

Orthogonal Proteomic Platforms and Their Implications for the Stable Classification of High-Grade Serous Ovarian Cancer Subtypes
por: Thomas, Stefani N., et al.
Publicado: (2020)

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
por: Colombo, Ilaria, et al.
Publicado: (2018)

Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status
por: Gadducci, Angiolo, et al.
Publicado: (2019)

Interferon-γ signaling is associated with BRCA1 loss-of-function mutations in high grade serous ovarian cancer
por: Cardenas, Horacio, et al.
Publicado: (2019)

Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer
por: Launonen, I.-M., et al.
Publicado: (2022)

PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
por: Konecny, G E, et al.
Publicado: (2016)

Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas
por: Sadlecki, Pawel, et al.
Publicado: (2018)

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
por: Hodgson, Darren R., et al.
Publicado: (2018)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines
por: Fleury, Hubert, et al.
Publicado: (2016)

Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance
por: Hurley, Rachel M, et al.
Publicado: (2021)

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting
por: Dougherty, Brian A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mnq7nu20jfqskp0k0u018ln1fm